BackgroundCervical cancer is the fourth commonest cancer affecting female population in the world, and the seventh most common cancer in the general population worldwide [1]. The disease is also the fourth leading cause of cancer death among women with 311,000 associated deaths in 2018. The highest regional incidence and mortality rates are seen in Africa, especially in Eastern (Malawi, with the highest mortality rate; and Zimbabwe) and Western Africa (Guinea, Burkina Faso, and Mali). Globally, it was previously admitted that low-and middle-income countries account for almost 90% of the burden of cervical cancer [2] due to insufficient awareness, lack of effective screening programs, and late clinical presentation. In addition, reports of trends in cervical cancer mortality in these countries have been limited by poor data quality and inaccurate estimates of population [3]. Additionally, in most of these countries, especially in sub-Saharan Africa, there is no cancer registry. Human papillomavirus (HPV) is a causative agent of cervical cancer that has been detected in 99.7% of cervical squamous cell carcinoma and in 94-100% of cervical adenocarcinoma [4]. HPV is transmitted through sexual intercourse or skin-to-skin genital contact [5], and persistent infection with high-risk HPV (HR-HPV) is the major cause of cervical intraepithelial neoplasia and invasive cervical cancer [6][7][8]. In general, most infections resolve on their own, as the immune response controls infection and prevents progression to precancerous lesions [9]. Papillomaviruses are circular, nonenveloped double-stranded DNA viruses with a genome length of 8 kb. More than 200 HPV genotypes have been reported and grouped into cutaneous and mucosal types according to their site of infection, and then subdivided into high risk (HR) and low risk (LR) types, depending on their association with a particular infection. Malignant disease (IARC,